BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37149016)

  • 1. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease.
    Rosso C; Caviglia GP; Birolo G; Armandi A; Pennisi G; Pelusi S; Younes R; Liguori A; Perez-Diaz-Del-Campo N; Nicolosi A; Govaere O; Castelnuovo G; Olivero A; Abate ML; Ribaldone DG; Fariselli P; Valenti L; Miele L; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3314-3321.e3. PubMed ID: 37149016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
    Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
    J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study.
    Seko Y; Yamaguchi K; Shima T; Iwaki M; Takahashi H; Kawanaka M; Tanaka S; Mitsumoto Y; Yoneda M; Nakajima A; Fjellström O; Blau JE; Carlsson B; Okanoue T; Itoh Y
    Liver Int; 2023 Oct; 43(10):2210-2219. PubMed ID: 37470077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease.
    Grimaudo S; Pipitone RM; Pennisi G; Celsa C; Cammà C; Di Marco V; Barcellona MR; Boemi R; Enea M; Giannetti A; Spatola F; Marchesini G; Craxì A; Petta S
    Clin Gastroenterol Hepatol; 2020 Apr; 18(4):935-944.e3. PubMed ID: 31419571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
    J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis.
    Tang S; Zhang J; Mei TT; Guo HQ; Wei XH; Zhang WY; Liu YL; Liang S; Fan ZP; Ma LX; Lin W; Liu YR; Qiu LX; Yu HB
    BMC Med Genet; 2020 Aug; 21(1):163. PubMed ID: 32811452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.
    Lee SS; Byoun YS; Jeong SH; Woo BH; Jang ES; Kim JW; Kim HY
    Dig Dis Sci; 2014 Dec; 59(12):2967-74. PubMed ID: 25069572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
    Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis.
    Urias E; Tedesco NR; Burkholder DA; Moran IJ; Miller MJ; Jasty VSJ; Patil S; Zoellner S; Wijarnpreecha K; Chen VL
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780253
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype.
    Tai J; Hsu CW; Chen WT; Yang SS; Chiu CH; Chien RN; Chang ML
    Cancer Sci; 2024 Feb; 115(2):564-574. PubMed ID: 38083881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis.
    Dai G; Liu P; Li X; Zhou X; He S
    Medicine (Baltimore); 2019 Feb; 98(7):e14324. PubMed ID: 30762732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
    World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B.
    Pan Q; Zhang RN; Wang YQ; Zheng RD; Mi YQ; Liu WB; Shen F; Chen GY; Lu JF; Zhu CY; Zhang SY; Chen YM; Sun WL; Fan JG
    World J Gastroenterol; 2015 Jul; 21(28):8605-14. PubMed ID: 26229402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.
    Walker RW; Belbin GM; Sorokin EP; Van Vleck T; Wojcik GL; Moscati A; Gignoux CR; Cho J; Abul-Husn NS; Nadkarni G; Kenny EE; Loos RJF
    J Hepatol; 2020 Jun; 72(6):1070-1081. PubMed ID: 32145261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients.
    Tai CM; Huang CK; Tu HP; Hwang JC; Yeh ML; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
    Medicine (Baltimore); 2016 Mar; 95(12):e3120. PubMed ID: 27015186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.